Srt 501.

Resveratrol is cleared very quickly by intestinal and hepatic glucuronidation and sulfation, which is why unmodified powder gives low parent-compound exposure. Piperine inhibits UDP-glucuronosyltransferase activity and has been used specifically to raise resveratrol plasma levels. The interaction is pharmacokinetic; it changes exposure, not any measured outcome.

Trans-resveratrol dissolves poorly in water, so dispersion in a lipid vehicle keeps more of the dose in solution through the gut. Medium-chain triglycerides are used for that purpose in soft-gel and emulsion formats. Micronisation, which is what defines this material, addresses the same limitation by a different route.

Phospholipids form dispersions that keep lipophilic polyphenols finely divided and available for micellar uptake. Lecithin-complexed resveratrol formats are built on that principle. This is a formulation relationship rather than a physiological one.

Quercetin and resveratrol are both handled by sulfotransferase and UGT enzymes in the gut wall. Taken together, each can occupy conjugation capacity the other would use, which tends to raise circulating parent compound for both. The direction is predictable from shared metabolism; the magnitude in people taking supplements has not been pinned down.

Curcumin has the same weakness as resveratrol: heavy glucuronidation before it reaches circulation. Co-dosing means two substrates competing for the same conjugating enzymes, which can raise exposure to both. Formulators often pair them for that reason alongside the same solubilising aids.

Pterostilbene is the dimethylated relative of resveratrol and is conjugated more slowly, so it persists longer after a dose. Pairing them puts two closely related stilbenes into the same formulation with different clearance profiles. The rationale is chemical; a head-to-head combination outcome study is not what supports it.

Resveratrol is described as a sirtuin-pathway modulator while NMN supplies substrate for NAD synthesis, and sirtuin activity depends on NAD availability. That makes co-formulation a coherent design choice on paper. It is mechanistic reasoning, not a measured combined effect.

Resveratrol has documented antiplatelet activity in laboratory work, and long-chain omega-3 fats affect platelet aggregation through eicosanoid chemistry. Stacking them means two inputs pushing the same direction on clotting behaviour. This is flagged as an additive effect to be aware of, not a benefit claim.

Grape seed extract supplies proanthocyanidins while resveratrol is a stilbene; both come from the same plant and both are metabolised heavily on first pass. Products often combine them to present a fuller grape polyphenol profile. Co-formulation is convention here rather than a measured interaction.

Phenolic radicals formed when a stilbene quenches an oxidant can be reduced back by ascorbate in vitro. Whether that recycling contributes anything measurable after an oral dose has not been established. Read it as chemistry observed in solution.